Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.67 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.67 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.61 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.61 |
| ▸ | NAT1 | P18440 | 5/20 | 0.60 |
| ▸ | MYC | P01106 | 2/20 | 0.60 |
| ▸ | MAX | P61244 | 2/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497530 | 1.00 | CSNK2A2 (0.67) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL1520306 | 1.00 | CSNK2A2 (0.67) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL30250232 | 0.92 | GSK3B (0.77) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL8177487 | 0.87 | CSNK2A2 (0.54) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL29369746 | 0.87 | GSK3B (0.83) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL1249096 | 0.87 | GSK3B (0.83) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL1249098 | 0.87 | GSK3B (0.83) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL2882197 | 0.87 | GSK3B (0.83) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL497019 | 0.83 | DYRK1A (0.67) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B | |
| SCHEMBL497020 | 0.83 | DYRK1A (0.67) | CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1648452-A1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005011686-A1 | 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
| WO-2000018748-A1 | RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CSNK2A2 3199/4885CSNK2B 3130/4885CSNK2A1 3460/4885 |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | PI4K2B, PI4KA, PTK2B | CSNK2A2 1038/4885CSNK2B 897/4885CSNK2A1 1006/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CSNK2A2 3464/4885CSNK2B 3387/4885CSNK2A1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.